Amyloidosis cutis dyschromica (ACD) is an extremely rare type of primary cutaneous amyloidosis. To date there are fewer than 40 published cases worldwide; some were reported affecting several family members. Its resemblance to other common pigmentation disorders makes it rarely recognized at first sight. Our patient, the 12-year-old firstborn son of non-consanguineous parents presented with generalized mottled pigmentation starting from lower extremities. His siblings suffered from similar condition. The clue for diagnosis is the amyloid deposition in the papillary dermis. The etiology of ACD is still unknown, but genetic factors and ultraviolet radiation are implicated. It is proposed that disturbance of keratinocyte repair following ultraviolet radiation results in amyloid deposition. The treatment remains a challenge. Oral acitretin treatment, thought to repair keratinization defect, gave a slight improvement in our case. Our is the first case of ACD reported in Indonesia.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224002 | PMC |
| http://dx.doi.org/10.4081/dr.2014.5375 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary Systemic Amyloidosis Characterized by Multiple Keratinous Cysts: A Case Report.
J Cutan Pathol
December 2024
Department of Dermatology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Article Synopsis
- A 67-year-old male presented with skin plaques and bruising on the neck and hands for 2 years, along with nail issues.
- Histopathological tests indicated the presence of keratinous cysts and eosinophilic material, which tested positive for Congo red staining.
- A bone marrow biopsy confirmed multiple myeloma, leading to a diagnosis of primary systemic amyloidosis alongside multiple myeloma.
Electrophysiological Monitoring of Asymptomatic Transthyretin Mutation Carriers.
Muscle Nerve
February 2025
Referral Centre for Neuromuscular Diseases and ALS, La Timone University Hospital, Aix-Marseille University, ERN Neuro-NMD, Marseille, France.
Introduction/aims: It is imperative to screen asymptomatic carriers of transthyretin (TTR) mutations to initiate treatment early. The protocol for repeated electrodiagnostic (EDX) assessments over time lacks standardization. Our aim was to report the electrophysiological evolution of a cohort of asymptomatic carriers and to determine which biomarkers were most sensitive to change.
View Article and Find Full Text PDFThe evaluation of Congo red staining combined with fluorescence microscopy in the diagnosis of primary cutaneous amyloidosis.
J Dermatol
December 2024
Department of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei, Anhui, China.
Primary cutaneous amyloidosis (PCA) is a chronic pruritic skin disease. The apple-green birefringence of Congo red-stained amyloid under a polarized light microscope (CR-PLM) remains the gold standard in the diagnosis of PCA. However, there are some limitations to this approach.
View Article and Find Full Text PDFA case presentation of widespread macular amyloidosis associated with dual hepatitis B and hepatitis C infection.
Dermatol Online J
August 2024
Department of Dermatology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Macular amyloidosis is a variant of primary localized cutaneous amyloidosis in which amyloid protein is believed to be derived from keratinocytes. The care of this variant generally focuses on addressing the associated symptoms without the need to assess for underlying disease. However, an increasing number of cases of primary localized cutaneous amyloidosis have been reported in association with systemic diseases, particularly autoimmune diseases.
View Article and Find Full Text PDFCase report: Abrocitinib: a potential therapeutic option for lichen amyloidosis associated with atopic dermatitis.
Front Immunol
November 2024
School of Medicine, Tongji University, Shanghai, China.
Lichen amyloidosis (LA) is a predominant type of primary cutaneous amyloidosis that is characterized by persistent and intense skin itching. Although multiple therapeutics strategies are available for its treatment, there is no standard treatment so far. Abrocitinib, an oral small-molecule Janus kinase 1 inhibitor, has been authorized for the treatment of severe atopic dermatitis (AD) and can also provide rapid relief from pruritus.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!